Ulipristal acetate taken 48-120 hours after intercourse for emergency contraception

Obstetrics and Gynecology

Volumn 115, Issue 2 PART 1, 2010, Pages 257-263

  Fine, Paul ^a   Mathé, Henri ^a   Ginde, Savita ^a   Cullins, Vanessa ^a   Morfesis, Johanna ^a   Gainer, Erin ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID; CHORIONIC GONADOTROPIN; ULIPRISTAL ACETATE; UNCLASSIFIED DRUG; POSTCOITUS CONTRACEPTIVE AGENT; PREGNANE DERIVATIVE; ULIPRISTAL;

ADULT; ARTICLE; DRUG EFFICACY; DRUG SAFETY; EMERGENCY CONTRACEPTION; FEMALE; HUMAN; MENSTRUATION; PREGNANCY RATE; PRIORITY JOURNAL; SEXUAL INTERCOURSE; CLINICAL TRIAL; DRUG EFFECT; MENSTRUAL CYCLE; MULTICENTER STUDY; PREGNANCY;

CONTRACEPTION, POSTCOITAL; CONTRACEPTIVES, POSTCOITAL, HORMONAL; FEMALE; HUMANS; MENSTRUAL CYCLE; NORPREGNADIENES; PREGNANCY;

EID: 76549096084     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/AOG.0b013e3181c8e2aa     Document Type: Article

References (14)

1. Wilcox AJ, Weinberg CR, Baird DD. Timing of sexual intercourse in relation to ovulation: effects on the probability of conception, survival of the pregnancy, and sex of the baby. N Engl J Med 1995;333:1517-21.
2. von Hertzen H, Piaggio G, Van Look PF. Emergency contraception with levonorgestrel or the Yuzpe regimen. Task Force on Postovulatory Methods of Fertility Regulation. Lancet 1998;352:1939.
3. von Hertzen H, Piaggio G, Ding J, Chen J, Song S, Bartfai G, et al. Low dose mifepristone and two regimens of levonorg-estrel for emergency contraception: a WHO multicentre randomised trial. Lancet 2002;360:1803-10.
4. Croxatto HB, Brache V, Pavez M, Cochon L, Forcelledo ML, Alvarez F, et al. Pituitary-ovarian function following the standard levonorgestrel emergency contraceptive dose or a single 0.75-mg dose given on the days preceding ovulation. Contraception 2004;70:442-50.
5. Marions L, Cekan SZ, Bygdeman M, Gemzell-Danielsson K. Effect of emergency contraception with levonorgestrel or mife-pristone on ovarian function. Contraception 2004;69:373-7.
6. Wilcox AJ, Baird DD, Dunson DB, McConnaughey DR, Kesner JS, Weinberg CR. On the frequency of intercourse around ovulation: evidence for biological influences. Hum Reprod 2004;19:1539-43.
7. Grimes D. Intrauterine devices. In: Hatcher RA, Trussell J, Nelson AL, Cates W Jr, Stewart FH, Kowal D, editors. Contraceptive technology. 18th ed. New York (NY): Ardent Media; 2004. p. 499-502.
8. Stratton P, Hartog B, Hajizadeh N, Piquion J, Sutherland D, Merino M, et al. A single mid-follicular dose of CDB-2914, a new antiprogestin, inhibits folliculogenesis and endometrial differentiation in normally cycling women. Hum Reprod 2000;15:1092-9.
9. Creinin MD, Schlaff W, Archer DF, Wan L, Frezieres R, Thomas M, et al. Progesterone receptor modulator for emergency contraception: a randomized controlled trial. Obstet Gynecol 2006;108:1089-97.
10. Trussell J, Rodriguez G, Ellertson C. New estimates of the effectiveness of the Yuzpe regimen of emergency contraception. Contraception 1998;57:363-9.
11. Agresti A, Coull BA. Approximate is better than "exact" for interval estimation of binomial proportion. Am Statist 1998; 52:119-26.
12. Piaggio G, von Hertzen H, Grimes DA, Van Look PF. Timing of emergency contraception with levonorgestrel or the Yuzpe regimen. Task Force on Postovulatory Methods of Fertility Regulation. Lancet 1999;353:721.
13. Center for Drug Evaluation and Research. Guidance for development of vaginal contraceptive drugs. January 27, 1995. Available at: http://www.fda.gov/downloads/Drugs/Guidance ComplianceRegulatoryInformation/ Guidances/ucm071704.pdf. Retrieved November 10, 2009.
14. Wilcox AJ, Dunson D, Baird DD. The timing of the "fertile window" in the menstrual cycle: day specific estimates from a prospective study. BMJ 2000;321:1259-62.